Medindia

X

Bionovo to Present at the Rodman & Renshaw 10th Annual Global Investment Conference

Wednesday, November 12, 2008 General News J E 4
Advertisement
EMERYVILLE, Calif., Nov. 11 Bionovo, Inc.(Nasdaq: BNVI), a pharmaceutical company focused on the discovery anddevelopment of safe and effective drugs in the areas of women's health andcancer, announced that Isaac Cohen, Chairman and CEO of Bionovo, will bepresenting an overview of the Company at the Rodman & Renshaw 10th AnnualGlobal Investment Conference on November 11, 2008 at 5:45 p.m. Eastern Time.The event will be held at the New York Palace Hotel in New York City.

The presentation will be webcast and can be viewed via Bionovo's websiteat http://bionovo.com/investors/events. A webcast replay will become availableshortly after the presentation ends and will continue to be accessible for 90days via Bionovo's website.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery anddevelopment of safe and effective treatments for women's health and cancer,markets with significant unmet needs and billions in potential annual revenue.The company applies its expertise in the biology of menopause and cancer todesign new drugs derived from botanical sources which have novel mechanisms ofaction. Based on the results of early and mid-stage clinical trials, Bionovobelieves they have discovered new classes of drug candidates within their richpipeline with the potential to be leaders in their markets. Bionovo isheadquartered in Emeryville, California and is traded on the NASDAQ CapitalMarket under the symbol BNVI. For more information about Bionovo and itsprograms, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to thebusiness of Bionovo, Inc. that can be identified by the use of forward-lookingterminology such as "believes," "expects," or similar expressions. Suchforward-looking statements involve known and unknown risks and uncertainties,including uncertainties relating to product development, efficacy and safety,regulatory actions or delays, the ability to obtain or maintain patent orother proprietary intellectual property protection, market acceptance,physician acceptance, third party reimbursement, future capital requirements,competition in general and other factors that may cause actual results to bematerially different from those described herein as anticipated, believed,estimated or expected. Certain of these risks and uncertainties are or will bedescribed in greater detail in our filings with the Securities and ExchangeCommission, which are available at http://www.sec.gov. Bionovo, Inc. is underno obligation (and expressly disclaims any such obligation) to update or alterits forward-looking statements whether as a result of new information, futureevents or otherwise.

SOURCE Bionovo, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Genomic Health to Present at Stephens Fall Investm...
S
Whole-House Air Cleaner May Help Prevent Asthma At...